FDX1 and neoplasm: In view of the diverse drug sensitivities in a wide variety of tumorous diseases in patients, we further divided clinical patients with different sensitivities to antitumor drugs into treatment groups, and the results implied that for high FDX1 levels, chemotherapy drugs with lower IC50 values, including erlotiib, salubnrinal, HG-6-64-1, MS-275, bortezornib, and WH-4-023, are excellent choices for tumorous patients.